SNDX•benzinga•
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $39
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 4, 2025 by benzinga